

Malignant Germ Cell International Consortium

Annual Meeting 1–4 October 2023

Edinburgh Training and Conference Venue
16 St Mary's St, Edinburgh, Scotland




In partnership with

Welcome

We are delighted to welcome you to the Malignant Germ Cell International Consortium 2023 Annual Meeting in Edinburgh, on behalf of the MaGIC Consortium.

We bring together colleagues from across the world to foster new understandings, exchange ideas, and explore future directions in research, treatment and care for young patients affected by germ cell tumours. We hope you have a productive and fun-filled time!



Mark Brougham
2023 Meeting Host



Lindsay Frazier
MaGIC Chair



James Nicholson
MaGIC Vice-Chair



Michelle Lockely
MaGIC Vice-Chair



Aditya Bagrodia
MaGIC Vice-Chair



Lindsay Klosterkemper
Program Manager MaGIC

Agenda

| Sunday, 1st October | |
|---------------------|--|
| 8:30 – 9:00 | Registration |
| 9:00 – 9:45 | Welcome and Introductions (Main room) |
| 9:45 – 10:30 | Keynote speaker (Main Room) Professor Hamish Wallace, Royal Hospital for Children and Young People, Edinburgh Fertility preservation for young women with cancer: Who is at risk and what can be offered? |
| 10:30 – 10:45 | Break |
| 10:45 – 11:30 | MaGIC Year in Review (Main Room) – Lindsay Frazier |
| 11:30 – 12:30 | The MaGIC Pediatric Cancer Data Commons (PCDC): Current Opportunities and New Horizons (Main Room) – Sam Volchenboun, Brian Furner, and Tyler Ketterl |
| 12:30 – 13:30 | Lunch |
| 13:30 – 14:15 | Updates on international GCT Clinical Trials (Main Room) <ul style="list-style-type: none">• AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs.Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors – Furqan Shaikh• P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs) – Farzana Pashankar• TIGER (ALLIANCE A031102): Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors – Darren Feldman |
| 14:15 – 14:45 | Panel discussion: International Trials: Lessons Learned (Main Room) – Darren Feldman, Lindsay Frazier, Farzana Pashankar, Furqan Shaikh, Sara Stoneham |
| 14:45 – 15:30 | Committee Break-out Meetings <ul style="list-style-type: none">• Cell and Animal Models (Main Room)• Optimizing Therapy in Seminoma and Dysgerminoma (OTIS) Trial Development (Room 2.1) |
| 15:30 – 15:45 | Break |
| 15:45 – 16:30 | Committee Break-out Meetings <ul style="list-style-type: none">• OTIS Trial Development (Room 2.1)• -omics and New Technology (Main Room)• Survivorship Committee (Room 2.3) |
| 18:00 | Bowling at Lane 7 |

Monday, 2nd October

| | |
|---------------|---|
| 8:15 – 9:45 | Executive Committee Meeting (invite only) |
| 9:00 – 9:45 | The Rally Foundation Poster Session |
| 9:45 – 10:00 | Welcome & Day 2 Agenda Overview (Main Room) |
| 10:00 – 10:30 | Clinical Trial Design Seminar: Pros and Cons of Using Historical Controls (Main Room) – Mark Krailo, Michelle Nuno |
| 10:30 – 11:30 | Clinical Trials in Development (Main Room) <ul style="list-style-type: none"> • PANTHER - Phase III Randomized trial of Adaptive Dose Intense Treatment for High-risk Germ Cell Tumors – Darren Feldman • Novel Agents for r/r GCT – Rachana Shah, Sam Funt • ASTX727 Trial – Rachana Shah |
| 11:30 – 11:45 | Break |
| 11:45 – 13:15 | The Rally Foundation Oral Abstract Presentations (Main Room) <ul style="list-style-type: none"> • Deciphering molecular and (epi-)genetic mechanisms and kinetics of yolk-sac tumor formation from embryonalcarcinoma. – Mara Kotthoff • An exploration of experiences of survivors of testicular cancer experiencing ejaculatory dysfunction following retroperitoneal lymph node dissection – a sub-study of the PREPARE clinical trial. – Ben Tran • Transcriptomics and mouse model of Sacrococcygeal Teratomas. – Ernesto Rojas • Outcome of Children with Extracranial Malignant Germ Cell Tumors by Response Status at the End of Induction. – Furqan Shaikh • Toward Recapitulating Carcinogenesis of Type II Germ Cell Tumors in Cell Culture Models. – Toshi Shioda • A Phase II Trial of Durvalumab and Tremelimumab for Relapsed/Refractory Germ Cell Tumors. – Samuel Funt • Analysis of a mouse germ cell tumor model establishes pluripotency-associated miRNAs (mouse miR-290-295/ human miR-371-373) as conserved serum biomarkers for germ cell cancer detection. – Robert Weiss • Testicular Germ Cell Tumour Cells Release MicroRNA-containing Extracellular Vesicles Resulting in Promalignant Changes in Cell of the Tumour Microenvironment. – Matthew Murray • Unraveling the Testicular Seminoma Tumor Microenvironment by Single-Cell RNA-sequencing. – Krinio Giannikou |
| 13:15 – 13:45 | Lunch |
| 13:45 – 14:30 | The Rally Foundation Poster Session |
| 14:30 – 15:30 | Committee Break-out Meetings <ul style="list-style-type: none"> • Biology-Developmental Therapeutics DVL Committee (Main Room) • PCDC Up Close: Come Learn How to "Make the Haggis" (Room 2.1) |
| 15:30 – 15:45 | Break |
| 15:45 – 17:00 | Committee Break-out Meetings <ul style="list-style-type: none"> • Biology-DVL Committee (Main Room) • MaGIC in Africa (Room 2.1) • Office Hours with Mark Krailo (Room 2.3) |
| 19:00 | Dinner at Brewhemia |

| Tuesday, 3rd October | |
|----------------------|--|
| 6:45 | Group run/hike to Arthur's Seat |
| 9:00 – 9:15 | Welcome & Day Agenda Overview (Main Room) |
| 9:15 – 10:00 | Committee Break-out Meetings <ul style="list-style-type: none"> • miRNA and Biomarkers (Main Room) • Good/Standard Risk Trial Development (Room 2.1) • Office Hours with Michelle Nuno (Room 2.3) |
| 10:05 – 10:15 | Break |
| 10:15 – 13:15 | Committee Break-out Meetings <ul style="list-style-type: none"> • Mechanisms in GCT Initiation, Progression and Therapeutic Response (Main Room) • Surgical Management: Teratoma and Other Issues (Room 2.1) • Survivorship Committee (Room 2.3) |
| 11:00 – 13:15 | Committee Meetings Summaries and Future Directions (Main Room) <ul style="list-style-type: none"> • MaGIC in Africa • OTIS Trial Development • Biology-DVL Committee • Good/Standard Risk Trial Development • Survivorship Committee • Surgical Management: Teratoma and Other Issues |
| 13:15 – 14:15 | Lunch |
| 14:15 – 15:15 | Breakthroughs and future directions in biology (Main Room) |
| 15:15 – 15:30 | Break |
| 15:30 – 16:30 | Strategic Planning - Breakout Sessions |
| 19:00 | Dinner at the Scotch Whisky Experience |

| Wednesday, 4th October | |
|------------------------|---|
| 9:00 – 10:15 | Strategic Planning Report-Outs (Main Room) |
| 10:15 – 10:30 | Break |
| 10:30 – 11:00 | Closing Remarks (Main Room) |
| 11:00 | Lunch |

We wish to thank our generous supporters and donors who have allowed this event to happen:

